NADPH/quinone oxidoreductase is a priority target of glioblastoma chemotherapy.

International journal of oncology

Volumn 16, Issue 2, 2000, Pages 295-303

  Okamura, T ^a   Kurisu, K ^a   Yamamoto, W ^a   Takano, H ^a   Nishiyama, M ^a  

^a HIROSHIMA UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DNA TOPOISOMERASE; ENZYME INHIBITOR; GLUTATHIONE; GLUTATHIONE TRANSFERASE; MITOMYCIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); TUBULIN; TUMOR PROTEIN;

ARTICLE; DRUG EFFECT; DRUG RESISTANCE; GENETICS; GLIOBLASTOMA; HUMAN; METABOLISM;

ANTINEOPLASTIC AGENTS; DNA TOPOISOMERASES, TYPE I; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; GLIOBLASTOMA; GLUTATHIONE; GLUTATHIONE TRANSFERASE; HUMANS; MITOMYCIN; NAD(P)H DEHYDROGENASE (QUINONE); NEOPLASM PROTEINS; TUBULIN;

MLCS; MLOWN;

EID: 0034134144     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.16.2.295     Document Type: Article

References (0)